Business

Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ZG006 Combined with HS-20093 for Injection, Either With or Without Adabepilimab Injection for the Treatment of Extensive-Stage Small Cell Lung Cancer

Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ZG006 Combined with HS-20093 for Injection, Either With or Without Adabepilimab Injection for the Treatment of Extensive-Stage Small Cell Lung Cancer

articleSuzhou Zelgen Biopharmaceuticals Co. Ltd. Class AApril 8, 20264/news/announcement-on-voluntary-disclosure-of-notice-of-approval-for-drug-clinical-trial-application-obtained-by-zg006-combined-with-hs-20093-for-injection-either-with-or-without-adabepilimab-injection-for-the-treatment-of-extensive-stage-small-cell-lung-cancer
Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ZG006 Combined with HS-20093 for Injection, Either With or Without Adabepilimab Injection for the Treatment of Extensive-Stage Small Cell Lung Cancer

About this update from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ZG006 Combined with HS-20093 for Injection, Either With or Without Adabepilimab Injection for the Treatment of Extensive-Stage Small Cell Lung Cancer The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A